New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small Bergen study favored NR; larger trial found parity
• NR and NMN convert to nicotinic acid via gut microbes
• Blood NAD rises, but functional outcomes remain inconclusive
• Exercise may outpace supplements for boosting NAD metabolism
• Premium NAD precursors cost far more than cheap niacin

Pulse Analysis

The NAD molecule has become a buzzword in longevity circles, spawning a multi‑billion‑dollar industry around two vitamin B3 derivatives: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Early animal work suggested each could replenish cellular NAD more efficiently than traditional niacin, prompting companies to market them as premium anti‑aging supplements. However, recent human data paint a more nuanced picture. A crossover trial with six volunteers reported a 2.3‑fold greater NAD increase with NR, yet a larger, double‑blind study of 65 participants found both NR and NMN doubled NAD levels without a statistically significant difference, indicating that the perceived superiority of NR may be an artifact of small sample size.

Mechanistic investigations have shifted the focus from direct cellular uptake to the role of the gut microbiome. Independent researchers in Norway, Princeton, and Japan have demonstrated that orally administered NR and NMN are rapidly de‑acetylated or de‑phosphorylated by intestinal bacteria, producing nicotinic acid—a cheaper, well‑known form of vitamin B3. This nicotinic acid then enters the Preiss‑Handler pathway, effectively converging the two supplements onto the same metabolic route. Isotope‑labeling studies confirm that when the microbiota are suppressed, the nicotinic‑acid signal disappears, underscoring the microbiome’s central role in mediating NAD‑boosting effects.

Clinically, the story is less compelling. Meta‑analyses of randomized trials in older adults show no meaningful gains in muscle mass, grip strength, gait speed, or metabolic health despite confirmed NAD elevation. A long‑COVID trial similarly reported no symptom improvement. These outcomes suggest that simply raising blood NAD is insufficient for functional benefits, especially when lifestyle interventions like regular exercise can naturally sustain NAD pools at a fraction of the cost. For investors and consumers, the implication is clear: the premium price tag on NR and NMN may not be justified, and the broader NAD‑boosting narrative should be evaluated against robust clinical evidence rather than surrogate biomarkers alone.